文献速递腹部MR

混合型肝细胞-胆管细胞癌:钆塞酸增强MR成像上LI-RADS v2017分类用于鉴别诊断与预后判断

Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
PubMed 文献 · Eur Radiol · 2018-06-28

本研究纳入病理证实的混合型肝细胞-胆管细胞癌70例与匹配肝细胞癌70例,由两名放射科医师在钆塞酸增强MRI上按LI-RADS v2017分类。结果显示61.4%的混合癌归为LR-M,37.1%归为LR-5/4;LR-5/4组早期复发率低于LR-M组,但无复发生存无显著差异。

要点

  • 混合型肝细胞-胆管细胞癌在钆塞酸增强MRI上可归为LR-M或非LR-M,并非均为LR-M。
  • 表现为LR-5/4的混合癌更常出现动脉期高增强、廓清和强化包膜等HCC主要征象。
  • LR-M组术后早期复发率高于LR-5/4组,但无复发生存无显著差异。

核心结论

  • 在钆塞酸增强MRI上,相当比例的混合型肝细胞-胆管细胞癌可被归为非LR-M;影像上模仿HCC的LR-5/4混合癌可能提示术后早期复发结局优于LR-M。

研究设计与样本

  • 研究纳入病理证实的混合型肝细胞-胆管细胞癌70例和匹配的肝细胞癌70例,均为HCC高危患者并接受钆塞酸增强MRI,由两名放射科医师对每个病灶进行LI-RADS分类。

关键影像表现/征象

  • 混合型肝细胞-胆管细胞癌LR-5/4组与LR-M组比较,动脉期高增强频率为96.2%(25/26)vs 58.1%(25/43),p=0.001。
  • 混合型肝细胞-胆管细胞癌LR-5/4组与LR-M组比较,廓清表现频率为80.8%(21/26)vs 48.8%(21/43),p=0.011。
  • 混合型肝细胞-胆管细胞癌LR-5/4组与LR-M组比较,强化包膜频率为34.6%(9/26)vs 11.6%(5/43),p=0.031。

诊断标准与关键数值

  • 混合型肝细胞-胆管细胞癌LI-RADS分类分布:LR-M 61.4%(43/70)、LR-5/4 37.1%(26/70)、LR-TIV 1.4%(1/70)。
  • 肝细胞癌LI-RADS分类分布:LR-M 10.0%(7/70)、LR-5/4 88.6%(62/70)、LR-TIV 1.4%(1/70)。

临床应用与阅片要点

  • 混合型肝细胞-胆管细胞癌可表现为LR-5/4而非仅LR-M,阅片时需注意其可模仿HCC的主要影像征象。
  • LI-RADS分类可能为混合型肝细胞-胆管细胞癌术后预后提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the performance of the Liver Imaging Reporting and Data System (LI-RADS) v2017 for combined hepatocellular cholangiocarcinoma (cHCC-CCA) in the differential diagnosis from hepatocellular carcinoma (HCC) and prediction of prognosis on gadoxetic acid-enhanced MRI (Gd-EOB-MRI).

METHODS: Patients at high risk of HCC with pathologically confirmed cHCC-CCAs (n = 70) and a matched control of HCCs (n = 70) who had undergone Gd-EOB-MRI were included. LI-RADS category was assigned for each lesion by two radiologists. Imaging features and surgical outcomes were compared between cHCC-CCAs of LR-M and LR-5/4 using the χ2 test or Fisher's exact test. Recurrence-free survival (RFS) was estimated using Kaplan-Meier survival curves and compared using the log-rank test.

RESULTS: cHCC-CCAs and HCCs were categorised as LR-M, LR-5/4 and LR-TIV in 61.4% (43/70), 37.1% (26/70) and 1.4% (1/70) and 10.0% (7/70), 88.6% (62/70) and 1.4% (1/70), respectively. cHCC-CCAs of LR-5/4, in comparison to LR-M, showed significantly higher frequencies of major HCC features: arterial hyperenhancement (96.2% (25/26) vs. 58.1% (25/43), p = 0.001), washout appearance (80.8% (21/26) vs. 48.8% (21/43), p = 0.011) and enhancing capsule (34.6% (9/26) vs. 11.6% (5/43), p = 0.031). After curative surgery, patients with cHCC-CCAs of LR-M showed a higher early recurrence rate (≤ 6 months) than did those with LR-5/4 (27.8% (10/36) vs. 4.8% (1/21), p = 0.041), whereas no significant difference was observed in RFS (log-rank p = 0.084).

CONCLUSIONS: By using LI-RADS on Gd-EOB-MRI, a substantial proportion of cHCC-CCAs can be categorised as non-LR-M. In addition, cHCC-CCAs mimicking HCCs on imaging (LR-5/4) may indicate better surgical outcomes with regard to early recurrence than those of LR-M.

KEY POINTS: • cHCC-CCAs can be categorised as either LR-M or non-LR-M on Gd-EOB-MRI. • cHCC-CCAs of LR-5/4 frequently demonstrate major HCC imaging features. • LI-RADS categorisation may provide prognostic information after surgery in cHCC-CCAs.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jeon SK, Joo I, Lee DH, et al. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol. 2018. PMID: 29955948. doi:10.1007/s00330-018-5605-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。